MALVERN, PA — Baudax Bio, Inc., (NASDAQ: BXRX) a pharmaceutical company focused on advancing non-opioid analgesics and other products for the hospital and other acute care settings, today announced that Gerri Henwood, the Company’s President and Chief Executive Officer, will present at the Piper Jaffray 31st Annual Healthcare Conference on Thursday, December 5, 2019 at 12:00 p.m. ET at the Lotte New York Palace.
A live and archived webcast of the Piper Jaffray presentation will be available on the Events page of the company’s website at https://www.baudaxbio.com/. The webcast will be archived for a period of 30 days following the conclusion of the live event.
Baudax Bio is a pharmaceutical company focused on therapeutics for acute care settings. The Company’s lead product candidate is a proprietary intravenous (IV) form of meloxicam, a non-opioid, long-acting preferential COX-2 inhibitor. IV meloxicam has successfully completed two pivotal Phase III clinical efficacy trials, a large double-blind placebo-controlled Phase III safety trial, four Phase II clinical efficacy trials, as well as other safety studies.
Upon IV meloxicam approval, ANJESOTM, will be a novel non-opioid option for the management of moderate to severe pain. As a non-opioid, IV meloxicam has the potential to overcome many of the issues associated with commonly prescribed opioid therapeutics, including respiratory depression, constipation, excessive nausea and vomiting, as well as having no addictive potential while maintaining meaningful analgesic effects for relief of pain. For more information please visit www.baudaxbio.com.
Source: Baudax Bio, 490 Lapp Road, Malvern PA 19355